Together, as a community, we can emphasize the importance of diagnostic testing as a critical step to reach the goal of an AIDS-free generation by 2030. Meeting UNAIDS elimination goals1 is impossible without testing.
ARTICLE
To address this challenge, many of the world's top relief and aid organizations have joined together with an ambitious goal: to end stop many diseases.
In 2014, Roche launched the Global Access Program to support the UNAIDS 2020 targets to address the HIV/AIDS epidemic. In 2019 the program was expanded to include solutions for other high-burden diseases Tuberculosis (TB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV). In response to the COVID-19 pandemic, the SARS-CoV-2 test was included into the program in 2021 to enable access to reliable testing for patients in lower- and middle-income countries (LMIC).
Roche continues to partner with national governments, local healthcare facilities, communities and international agencies, including UNAIDS, CHAI, Unitaid, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund, and Centers for Disease Control (CDC) to help strengthen health system capacity beyond the provision of diagnostic tests.
Together, as a community, we can emphasize the importance of diagnostic testing as a critical step to reach the goal of an AIDS-free generation by 2030. Meeting UNAIDS elimination goals1 is impossible without testing.
References